- Home
- PLBC vs ANNX Comparison
PLBC vs ANNX Comparison
Compare PLBC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- ANNX
- Stock Information
- Founded
- PLBC 1980
- ANNX 2011
- Country
- PLBC United States
- ANNX United States
- Employees
- PLBC N/A
- ANNX N/A
- Industry
- PLBC Finance Companies
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- ANNX Health Care
- Exchange
- PLBC Nasdaq
- ANNX Nasdaq
- Market Cap
- PLBC 236.7M
- ANNX 263.3M
- IPO Year
- PLBC 2005
- ANNX 2020
- Fundamental
- Price
- PLBC $45.89
- ANNX $2.56
- Analyst Decision
- PLBC Buy
- ANNX Strong Buy
- Analyst Count
- PLBC 4
- ANNX 4
- Target Price
- PLBC $55.75
- ANNX $12.50
- AVG Volume (30 Days)
- PLBC 14.5K
- ANNX 1.8M
- Earning Date
- PLBC 07-21-2025
- ANNX 08-11-2025
- Dividend Yield
- PLBC 2.62%
- ANNX N/A
- EPS Growth
- PLBC 3.33
- ANNX N/A
- EPS
- PLBC 4.95
- ANNX N/A
- Revenue
- PLBC $84,001,000.00
- ANNX N/A
- Revenue This Year
- PLBC $19.95
- ANNX N/A
- Revenue Next Year
- PLBC $22.19
- ANNX N/A
- P/E Ratio
- PLBC $9.26
- ANNX N/A
- Revenue Growth
- PLBC 9.14
- ANNX N/A
- 52 Week Low
- PLBC $35.16
- ANNX $1.29
- 52 Week High
- PLBC $51.33
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- PLBC 55.23
- ANNX 54.40
- Support Level
- PLBC $45.40
- ANNX $1.85
- Resistance Level
- PLBC $46.34
- ANNX $2.97
- Average True Range (ATR)
- PLBC 1.24
- ANNX 0.27
- MACD
- PLBC 0.13
- ANNX 0.00
- Stochastic Oscillator
- PLBC 52.66
- ANNX 60.32
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.